Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 3/20 | 0.55 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.55 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.53 |
| ▸ | FAAH | O00519 | 3/20 | 0.51 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21204364 | 1.00 | LPAR1 (0.55) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL21204352 | 1.00 | LPAR1 (0.55) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL16639380 | 1.00 | LPAR1 (0.55) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL18687863 | 0.93 | LPAR1 (0.68) | LPAR1LPAR2ENPP2EPHX2SLC6A5 | |
| SCHEMBL21204363 | 0.92 | CASP2 (0.56) | LPAR1LPAR2ENPP2CASP2LPAR3 | |
| SCHEMBL19500013 | 0.88 | SLC6A5 (0.49) | LPAR1LPAR2ENPP2LPAR3TSHR | |
| SCHEMBL21204356 | 0.88 | LPAR1 (0.54) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL21204365 | 0.88 | LPAR1 (0.54) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL9844141 | 0.88 | LPAR1 (0.54) | LPAR1LPAR2ENPP2CASP2FAAH | |
| SCHEMBL21887657 | 0.87 | CASP2 (0.54) | LPAR1LPAR2ENPP2CASP2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024153-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20190247414-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2019-08-15 | — | — | US | disclosed |
| EP-3517610-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | National University Corporation Tokyo Medical and Dental University (JP) | 2019-07-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190247414-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | FABP7, NR2E3, SREBF2 | LPAR1 653/4885LPAR2 309/4885ENPP2 1588/4885 |
| US-20230024153-A1 | BLOOD-BRAIN BARRIER PERMEABLE HETERODUPLEX NUCLEIC ACID | FABP7, NR2E3, SREBF2 | LPAR1 653/4885LPAR2 309/4885ENPP2 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.